Esomeprazole
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
The S-enantiomer of omeprazole, esomeprazole is a potent proton pump inhibitor used to treat GERD, erosive esophagitis, peptic ulcers, and as part of H. pylori eradication therapy. It provides more consistent acid suppression compared to racemic omeprazole due to reduced first-pass hepatic metabolism.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
The S-enantiomer of omeprazole, esomeprazole is a potent proton pump inhibitor used to treat GERD, erosive esophagitis, peptic ulcers, and as part of H. NutriStack rates the supporting evidence as strong. Common adult dosing is 20–40 mg once daily for 4–8 weeks (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete magnesium, vitamin b12, calcium. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: healing of erosive esophagitis, maintenance of healed erosive esophagitis, symptomatic relief of gerd. 10 sources indexed (2006–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Irreversibly inhibits the hydrogen/potassium ATPase (H+/K+ ATPase) enzyme system on the secretory surface of gastric parietal cells. As the pure S-isomer, it has higher bioavailability than racemic omeprazole, producing more sustained suppression of gastric acid secretion over a 24-hour period.
Dosing & protocol.
Take at least 1 hour before meals; swallow capsules whole or open and mix granules with applesauce
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Magnesium
SignificantChronic acid suppression impairs active intestinal magnesium transport, especially via TRPM6/7-mediated uptake.
Vitamin B12
ModerateReduced gastric acid impairs release of food-bound vitamin B12 from proteins, lowering long-term absorption.
Calcium
ModerateLower gastric acidity reduces dissolution and absorption of less-soluble calcium salts, especially calcium carbonate.
Iron
ModerateReduced gastric acidity lowers conversion and solubility of non-heme iron, decreasing long-term absorption.
Full safety detail.
Side effects
- Headache
- Diarrhea
- Nausea
- Flatulence
- Abdominal pain
- Dry mouth
- Hypomagnesemia with prolonged therapy
- Increased fracture risk with long-term use
- Increased risk of C. difficile infection
- Vitamin B12 deficiency with long-term use
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
2- 1Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pyloriPMIDWang Y, Dai X, Gao C et al. · Helicobacter · 2023
Wang Y, Dai X, Gao C et al.. Network meta-analysis of different dosages of esomeprazole and rabeprazole for the treatment of Helicobacter pylori. Helicobacter. 2023
- 2Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trialsPMIDGralnek IM, Dulai GS, Fennerty MB et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2006
Gralnek IM, Dulai GS, Fennerty MB et al.. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2006
Randomized controlled trials
3- 3Efficacy and safety of tegoprazan (LXI-15028) vs . esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trialPMIDZhu H, Xue Q, Song Y et al. · Chinese medical journal · 2025
Zhu H, Xue Q, Song Y et al.. Efficacy and safety of tegoprazan (LXI-15028) vs . esomeprazole in patients with erosive esophagitis: A multicenter, randomized, double-blind, non-inferiority phase Ⅲ trial. Chinese medical journal. 2025
- 4Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III StudyPMIDLim H, Lee JY, Kwon YH et al. · Gut and liver · 2025
Lim H, Lee JY, Kwon YH et al.. Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study. Gut and liver. 2025
- 5Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory TrialPMIDKang N, Kang MG, Lee SE et al. · Lung · 2025
Kang N, Kang MG, Lee SE et al.. Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial. Lung. 2025
Reference material
5- 6Kahrilas PJ et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients. Aliment Pharmacol Ther. 2000.Source linkedPMID
- 7Sachar H et al. Proton pump inhibitors: risks of long-term use. J Fam Pract. 2013.Source linkedPMID
- 8Metz DC et al. Clinical pharmacokinetics of esomeprazole. Clin Pharmacokinet. 2006.Source linkedPMID
- 9Oh JH, Kim HS, Cheung DY et al.. Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared With Esomeprazole in Erosive Esophagitis. The American journal of gastroenterology. 2025Source linkedPMID
- 10Lee KN, Lee OY, Chun HJ et al.. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis. World journal of gastroenterology. 2022Source linkedPMID
Common questions.
Quick answers about Esomeprazole, drawn from the data on this page.
What is Esomeprazole?
The S-enantiomer of omeprazole, esomeprazole is a potent proton pump inhibitor used to treat GERD, erosive esophagitis, peptic ulcers, and as part of H. pylori eradication therapy. It provides more consistent acid suppression compared to racemic omeprazole due to reduced first-pass hepatic metabolism.
What is Esomeprazole used for?
Commonly cited benefits of Esomeprazole include: Healing of erosive esophagitis; Maintenance of healed erosive esophagitis; Symptomatic relief of GERD; H. pylori eradication (triple therapy); Risk reduction of NSAID-associated gastric ulcers. NutriStack rates the overall evidence as strong.
What is a typical dose of Esomeprazole?
A typical adult dose of Esomeprazole is 20–40 mg once daily for 4–8 weeks (as prescribed by your physician). The commonly recommended form is Delayed-release capsule or oral suspension. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Esomeprazole?
Reported side effects include headache, diarrhea, nausea, flatulence, abdominal pain, dry mouth. This is educational information; check with a healthcare professional before use.
How strong is the evidence for Esomeprazole?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Esomeprazole in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.